# A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor

> **NCT02717741** · PHASE1 · UNKNOWN · sponsor: **Nanjing Yoko Biomedical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** tafetinib

## Key facts

- **NCT ID:** NCT02717741
- **Lead sponsor:** Nanjing Yoko Biomedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-05
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02717741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02717741, "A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02717741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*